Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients.

Leukemia research - 1 Mar 2022

Park Hyunkyung, Kang Sungbong, Kim Inho, Kim Sangsoo, Kim Hyeong-Joon, Shin Dong-Yeop, Kim Dae-Young, Lee Kyoo-Hyung, Ahn Jae-Sook, Sohn Sang-Kyun, Lee Jeong-Ok, Cheong June-Won, Kim Kyoung Ha, Kim Hoon-Gu, Kim Hawk, Lee Yoo Jin, Nam Seung-Hyun, Do Young Rok, Park Sang-Gon, Park Seong Kyu, Song Hun Ho, Jung Chul Won, Park Seonyang

Abstract excerpt

Genetic differences may be associated with the response to tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia (CML). In this study, we identified genetic alterations between rapid and slow responders (BCR/ABL1 International Scale at 6 months: ≤0.1 % vs. > 0.1 %) of TKI treatment in chronic phase CML patients. Our analyses involved single nucleotide polymorphism (SNP), a Genome Wide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Killer Cells, Natural

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 35101736
DOI: 10.1016/j.leukres.2022.106791

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients.PMID 35101736Read ↗

Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemiaSemantic proximity Read ↗

Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.Semantic proximity Read ↗

T Cell-Mediated Tumor Killing Sensitivity Gene Signature-Based Prognostic Score For Acute Myeloid LeukemiaSemantic proximity Read ↗

Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.Semantic proximity Read ↗

Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia.Semantic proximity Read ↗

Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia.Semantic proximity Read ↗

Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics StudySemantic proximity Read ↗

Genetic mutations and immune microenvironment: unveiling the connection to AML prognosis.Semantic proximity Read ↗

Immune-Related Genes for the Prediction of Response to Imatinib therapy in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Bioinformatics analysis and identification of hub genes and immune-related molecular mechanisms in chronic myeloid leukemiaSemantic proximity Read ↗

Identification of Common Genes and Pathways Underlying Imatinib and Nilotinib Treatment in CML: a Bioinformatics StudySemantic proximity Read ↗

Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.